IQVIA Holdings Inc.


SKU: IQV-1 Category:


IQVIA Holdings Inc. delivered a mixed result in the recent quarter, with revenues below market expectations, but it managed to surpass the analyst consensus in terms of earnings. Despite its continuous expansion, revenue failed to meet IQVIA’s expectations in the TAS business. Approximately half of the revenue shortfall stemmed from foreign exchange challenges, while the remaining half resulted from persistent demand weakness in the TAS segment. Despite this shortfall, efficient productivity measures enabled the company to meet profit guidance. In the TAS business, notable analytics contracts were secured, including providing analytics for a top pharma client’s women’s health product and winning a US data analytics contract with a decade-long customer. The clinical development segment witnessed robust demand in the R&DS segment, with net new bookings exceeding $2.6 billion, reflecting a quarterly book-to-bill ratio of 1.24x. IQVIA’s partnership with Salesforce remains strong, covering clinical and commercial offerings. Multiple rare disease studies were awarded worldwide, demonstrating expertise and differentiated offerings. In R&DS, strategic collaborations with CEPI and Argenx and significant wins in oncology were highlighted, showcasing IQVIA’s prowess in clinical research and development.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!